Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

A new formulation of the best-selling cancer drug, Keytruda, appears to deliver similar blood levels of the medicine when it ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Among 64 patients who received immune checkpoint inhibitors, 78% had downstaging of their liver tumor to within Milan ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...